<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31028115</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1529-2401</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>26</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title>
          <ISOAbbreviation>J Neurosci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cholinergic Neurons of the Medial Septum Are Crucial for Sensorimotor Gating.</ArticleTitle>
        <Pagination>
          <StartPage>5234</StartPage>
          <EndPage>5242</EndPage>
          <MedlinePgn>5234-5242</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0950-18.2019</ELocationID>
        <Abstract>
          <AbstractText>Hypofunction of NMDA receptors has been considered a possible cause for the pathophysiology of schizophrenia. More recently, indirect ways to regulate NMDA that would be less disruptive have been proposed and metabotropic glutamate receptor subtype 5 (mGluR5) represents one such candidate. To characterize the cell populations involved, we demonstrated here that knock-out (KO) of mGluR5 in cholinergic, but not glutamatergic or parvalbumin (PV)-positive GABAergic, neurons reduced prepulse inhibition of the startle response (PPI) and enhanced sensitivity to MK801-induced locomotor activity. Inhibition of cholinergic neurons in the medial septum by DREADD (designer receptors exclusively activated by designer drugs) resulted in reduced PPI further demonstrating the importance of these neurons in sensorimotor gating. Volume imaging and quantification were used to compare PV and cholinergic cell distribution, density, and total cell counts in the different cell-type-specific KO lines. Electrophysiological studies showed reduced NMDA receptor-mediated currents in cholinergic neurons of the medial septum in mGluR5 KO mice. These results obtained from male and female mice indicate that cholinergic neurons in the medial septum represent a key cell type involved in sensorimotor gating and are relevant to pathologies associated with disrupted sensorimotor gating such as schizophrenia.<b>SIGNIFICANCE STATEMENT</b> The mechanistic complexity underlying psychiatric disorders remains a major challenge that is hindering the drug discovery process. Here, we generated genetically modified mouse lines to better characterize the involvement of the receptor mGluR5 in the fine-tuning of NMDA receptors, specifically in the context of sensorimotor gating. We evaluated the importance of knocking-out mGluR5 in three different cell types in two brain regions and performed different sets of experiments including behavioral testing and electrophysiological recordings. We demonstrated that cholinergic neurons in the medial septum represent a key cell-type involved in sensorimotor gating. We are proposing that pathologies associated with disrupted sensorimotor gating, such as with schizophrenia, could benefit from further evaluating strategies to modulate specifically cholinergic neurons in the medial septum.</AbstractText>
          <CopyrightInformation>Copyright © 2019 the authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Junghee</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-1204-097X</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Jia</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-9639-5187</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Ko-Woon</ForeName>
            <Initials>KW</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amreen</LastName>
            <ForeName>Bushra</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McCabe</LastName>
            <ForeName>Kathryn A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pitcher</LastName>
            <ForeName>Clark</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liebmann</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Greengard</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flajolet</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065 marc.flajolet@rockefeller.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P50 MH090963</GrantID>
            <Acronym>MH</Acronym>
            <Agency>NIMH NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>04</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurosci</MedlineTA>
        <NlmUniqueID>8102140</NlmUniqueID>
        <ISSNLinking>0270-6474</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064529">Receptor, Metabotropic Glutamate 5</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6LR8C1B66Q</RegistryNumber>
          <NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059329" MajorTopicYN="N">Cholinergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065808" MajorTopicYN="N">Prepulse Inhibition</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064529" MajorTopicYN="N">Receptor, Metabotropic Glutamate 5</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013216" MajorTopicYN="N">Reflex, Startle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055139" MajorTopicYN="N">Sensory Gating</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">NMDA</Keyword>
        <Keyword MajorTopicYN="Y">cholinergic</Keyword>
        <Keyword MajorTopicYN="Y">gating</Keyword>
        <Keyword MajorTopicYN="Y">mGluR5</Keyword>
        <Keyword MajorTopicYN="Y">sensorimotor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31028115</ArticleId>
        <ArticleId IdType="pmc">PMC6595952</ArticleId>
        <ArticleId IdType="doi">10.1523/JNEUROSCI.0950-18.2019</ArticleId>
        <ArticleId IdType="pii">JNEUROSCI.0950-18.2019</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Aloisi E, Le Corf K, Dupuis J, Zhang P, Ginger M, Labrousse V, Spatuzza M, Georg Haberl M, Costa L, Shigemoto R, Tappe-Theodor A, Drago F, Vincenzo Piazza P, Mulle C, Groc L, Ciranna L, Catania MV, Frick A (2017) Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice. Nat Commun
8:1103. 10.1038/s41467-017-01191-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-01191-2</ArticleId>
            <ArticleId IdType="pmc">PMC5653653</ArticleId>
            <ArticleId IdType="pubmed">29062097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barnes SA, Pinto-Duarte A, Kappe A, Zembrzycki A, Metzler A, Mukamel EA, Lucero J, Wang X, Sejnowski TJ, Markou A, Behrens MM (2015) Disruption of mGluR5 in parvalbumin-positive interneurons induces core features of neurodevelopmental disorders. Mol Psychiatry
20:1161–1172. 10.1038/mp.2015.113
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2015.113</ArticleId>
            <ArticleId IdType="pmc">PMC4583365</ArticleId>
            <ArticleId IdType="pubmed">26260494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bonsi P, Cuomo D, De Persis C, Centonze D, Bernardi G, Calabresi P, Pisani A (2005) Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons. Neuropharmacology
49:104–113. 10.1016/j.neuropharm.2005.05.012
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2005.05.012</ArticleId>
            <ArticleId IdType="pubmed">16005029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brody SA, Conquet F, Geyer MA (2003) Disruption of prepulse inhibition in mice lacking mGluR1. Eur J Neurosci
18:3361–3366. 10.1111/j.1460-9568.2003.03073.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1460-9568.2003.03073.x</ArticleId>
            <ArticleId IdType="pubmed">14686909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brody SA, Dulawa SC, Conquet F, Geyer MA (2004) Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry
9:35–41. 10.1038/sj.mp.4001404
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.mp.4001404</ArticleId>
            <ArticleId IdType="pubmed">14699440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C (2008) Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev
32:1014–1023. 10.1016/j.neubiorev.2008.03.012
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2008.03.012</ArticleId>
            <ArticleId IdType="pubmed">18471877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bygrave AM, Masiulis S, Nicholson E, Berkemann M, Barkus C, Sprengel R, Harrison PJ, Kullmann DM, Bannerman DM, Kätzel D (2016) Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801. Transl Psychiatry. 6:e778. 10.1038/tp.2016.44
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/tp.2016.44</ArticleId>
            <ArticleId IdType="pmc">PMC4872402</ArticleId>
            <ArticleId IdType="pubmed">27070406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheng J, Xiong Z, Duffney LJ, Wei J, Liu A, Liu S, Chen GJ, Yan Z (2014) Methylphenidate exerts dose-dependent effects on glutamate receptors and behaviors. Biol Psychiatry
76:953–962. 10.1016/j.biopsych.2014.04.003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopsych.2014.04.003</ArticleId>
            <ArticleId IdType="pmc">PMC4194277</ArticleId>
            <ArticleId IdType="pubmed">24832867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Clarke PB, Reuben M (1995) Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter. Br J Pharmacol
114:315–322. 10.1111/j.1476-5381.1995.tb13229.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.1995.tb13229.x</ArticleId>
            <ArticleId IdType="pmc">PMC1510234</ArticleId>
            <ArticleId IdType="pubmed">7881731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Conn PJ, Lindsley CW, Jones CK (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci
30:25–31. 10.1016/j.tips.2008.10.006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tips.2008.10.006</ArticleId>
            <ArticleId IdType="pmc">PMC2907735</ArticleId>
            <ArticleId IdType="pubmed">19058862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corti C, Xuereb JH, Crepaldi L, Corsi M, Michielin F, Ferraguti F (2011) Altered levels of glutamatergic receptors and Na+/K+ ATPase-1 in the prefrontal cortex of subjects with schizophrenia. Schizophr Res
128:7–14. 10.1016/j.schres.2011.01.021
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.schres.2011.01.021</ArticleId>
            <ArticleId IdType="pubmed">21353485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry
48:381–388. 10.1016/S0006-3223(00)00918-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0006-3223(00)00918-5</ArticleId>
            <ArticleId IdType="pubmed">10978721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002) Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry
7:1083–1091. 10.1038/sj.mp.4001199
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.mp.4001199</ArticleId>
            <ArticleId IdType="pubmed">12476323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH (2013) Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry
18:1199–1204. 10.1038/mp.2012.194
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2012.194</ArticleId>
            <ArticleId IdType="pmc">PMC3646075</ArticleId>
            <ArticleId IdType="pubmed">23337947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Geyer MA. (2006) The family of sensorimotr gating disorders: comorbidities or diagnostic overlaps?
Neurotox Res
10:211–220. 10.1007/BF03033358
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03033358</ArticleId>
            <ArticleId IdType="pmc">PMC2667105</ArticleId>
            <ArticleId IdType="pubmed">17197371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gorski JA, Talley T, Qiu M, Puelles L, Rubenstein JL, Jones KR (2002) Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J Neurosci
22:6309–6314. 10.1523/JNEUROSCI.22-15-06309.2002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.22-15-06309.2002</ArticleId>
            <ArticleId IdType="pmc">PMC6758181</ArticleId>
            <ArticleId IdType="pubmed">12151506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH (2005) Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse
57:123–131. 10.1002/syn.20164
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/syn.20164</ArticleId>
            <ArticleId IdType="pubmed">15945063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gururajan A, Taylor DA, Malone DT (2010) Effect of testing conditions on the propsychotic action of MK-801 on prepulse inhibition, social behaviour and locomotor activity. Physiol Behav
99:131–138. 10.1016/j.physbeh.2009.11.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.physbeh.2009.11.005</ArticleId>
            <ArticleId IdType="pubmed">19931287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A (2002) The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology
43:1199–1209. 10.1016/S0028-3908(02)00332-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0028-3908(02)00332-5</ArticleId>
            <ArticleId IdType="pubmed">12527469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hippenmeyer S, Vrieseling E, Sigrist M, Portmann T, Laengle C, Ladle DR, Arber S (2005) A developmental switch in the response of DRG neurons to ETS transcription factor signaling. PLoS Biol
3:e159. 10.1371/journal.pbio.0030159
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.0030159</ArticleId>
            <ArticleId IdType="pmc">PMC1084331</ArticleId>
            <ArticleId IdType="pubmed">15836427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Iravani MM, Muscat R, Kruk ZL (1999) MK-801 interaction with the 5-HT transporter: a real-time study in brain slices using fast cyclic voltammetry. Synapse
32:212–224. 10.1002/(SICI)1098-2396(19990601)32:3&lt;212::AID-SYN7&gt;3.0.CO;2-M
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1098-2396(19990601)32:3&lt;212::AID-SYN7&gt;3.0.CO;2-M</ArticleId>
            <ArticleId IdType="pubmed">10340631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jadi MP, Behrens MM, Sejnowski TJ (2016) Abnormal gamma oscillations in N-methyl-d-aspartate receptor hypofunction models of schizophrenia. Biol Psychiatry
79:716–726. 10.1016/j.biopsych.2015.07.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopsych.2015.07.005</ArticleId>
            <ArticleId IdType="pmc">PMC4720598</ArticleId>
            <ArticleId IdType="pubmed">26281716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Justus D, Dalügge D, Bothe S, Fuhrmann F, Hannes C, Kaneko H, Friedrichs D, Sosulina L, Schwarz I, Elliott DA, Schoch S, Bradke F, Schwarz MK, Remy S (2017) Glutamatergic synaptic integration of locomotion speed via septoentorhinal projections. Nat Neurosci
20:16–19. 10.1038/nn.4447
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn.4447</ArticleId>
            <ArticleId IdType="pubmed">27893726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, Conn PJ (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther
306:116–123. 10.1124/jpet.103.048702
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.103.048702</ArticleId>
            <ArticleId IdType="pubmed">12660307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther
313:199–206. 10.1124/jpet.104.079244
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.104.079244</ArticleId>
            <ArticleId IdType="pubmed">15608073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee KW, Westin L, Kim J, Chang JC, Oh YS, Amreen B, Gresack J, Flajolet M, Kim D, Aperia A, Kim Y, Greengard P (2015) Alteration by p11 of mGluR5 localization regulates depression-like behaviors. Mol Psychiatry
20:1546–1556. 10.1038/mp.2015.132
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2015.132</ArticleId>
            <ArticleId IdType="pmc">PMC4907335</ArticleId>
            <ArticleId IdType="pubmed">26370144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liebmann T, Renier N, Bettayeb K, Greengard P, Tessier-Lavigne M, Flajolet M (2016) Three-dimensional study of Alzheimer's disease hallmarks using the iDISCO clearing method. Cell Rep
16:1138–1152. 10.1016/j.celrep.2016.06.060
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.06.060</ArticleId>
            <ArticleId IdType="pmc">PMC5040352</ArticleId>
            <ArticleId IdType="pubmed">27425620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lindsley CW, Stauffer SR (2013) Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004–2012). Pharm Pat Anal
2:93–108. 10.4155/ppa.12.82
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4155/ppa.12.82</ArticleId>
            <ArticleId IdType="pubmed">24236973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL Jr, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem
47:5825–5828. 10.1021/jm049400d
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm049400d</ArticleId>
            <ArticleId IdType="pubmed">15537338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
López-Bendito G, Shigemoto R, Fairen A, Luján R (2002) Differential distribution of group I metabotropic glutamate receptors during rat cortical development. Cereb Cortex
12:625–638. 10.1093/cercor/12.6.625
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cercor/12.6.625</ArticleId>
            <ArticleId IdType="pubmed">12003862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maksymetz J, Moran SP, Conn PJ (2017) Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. Mol Brain
10:15. 10.1186/s13041-017-0293-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13041-017-0293-z</ArticleId>
            <ArticleId IdType="pmc">PMC5405554</ArticleId>
            <ArticleId IdType="pubmed">28446243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matosin N, Newell KA (2013) Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci Biobehav Rev
37:256–268. 10.1016/j.neubiorev.2012.12.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2012.12.005</ArticleId>
            <ArticleId IdType="pubmed">23253944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matosin N, Fernandez-Enright F, Lum JS, Newell KA (2017) Shifting towards a model of mGluR5 dysregulation in schizophrenia: consequences for future schizophrenia treatment. Neuropharmacology
115:73–91. 10.1016/j.neuropharm.2015.08.003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2015.08.003</ArticleId>
            <ArticleId IdType="pubmed">26349010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mori F, Okada KI, Nomura T, Kobayashi Y (2016) The pedunculopontine tegmental nucleus as a motor and cognitive interface between the cerebellum and basal ganglia. Front Neuroanat
10:109. 10.3389/fnana.2016.00109
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnana.2016.00109</ArticleId>
            <ArticleId IdType="pmc">PMC5097925</ArticleId>
            <ArticleId IdType="pubmed">27872585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muñoz-Manchado AB, Bengtsson Gonzales C, Zeisel A, Munguba H, Bekkouche B, Skene NG, Lönnerberg P, Ryge J, Harris KD, Linnarsson S, Hjerling-Leffler J (2018) Diversity of interneurons in the dorsal striatum revealed by single-cell RNA sequencing and PatchSeq. Cell Rep
24:2179–2190.e7. 10.1016/j.celrep.2018.07.053
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.07.053</ArticleId>
            <ArticleId IdType="pmc">PMC6117871</ArticleId>
            <ArticleId IdType="pubmed">30134177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Paylor R, Crawley JN (1997) Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology
132:169–180. 10.1007/s002130050333
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s002130050333</ArticleId>
            <ArticleId IdType="pubmed">9266614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pietraszek M, Nagel J, Gravius A, Schäfer D, Danysz W (2007) The role of group I metabotropic glutamate receptors in schizophrenia. Amino Acids
32:173–178. 10.1007/s00726-006-0319-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00726-006-0319-9</ArticleId>
            <ArticleId IdType="pubmed">16699816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pisani A, Bonsi P, Centonze D, Bernardi G, Calabresi P (2001) Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons. Neuropharmacology
40:460–463. 10.1016/S0028-3908(00)00184-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0028-3908(00)00184-2</ArticleId>
            <ArticleId IdType="pubmed">11166340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, Egan MF, Coppola R, Weinberger DR (2003) In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry
160:118–127. 10.1176/appi.ajp.160.1.118
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.ajp.160.1.118</ArticleId>
            <ArticleId IdType="pubmed">12505810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ramoa AS, Alkondon M, Aracava Y, Irons J, Lunt GG, Deshpande SS, Wonnacott S, Aronstam RS, Albuquerque EX (1990) The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J Pharmacol Exp Ther
254:71–82. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1694895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Renier N, Wu Z, Simon DJ, Yang J, Ariel P, Tessier-Lavigne M (2014) iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell
159:896–910. 10.1016/j.cell.2014.10.010
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.10.010</ArticleId>
            <ArticleId IdType="pubmed">25417164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rook JM, Xiang Z, Lv X, Ghoshal A, Dickerson JW, Bridges TM, Johnson KA, Foster DJ, Gregory KJ, Vinson PN, Thompson AD, Byun N, Collier RL, Bubser M, Nedelcovych MT, Gould RW, Stauffer SR, Daniels JS, Niswender CM, Lavreysen H, et al.  (2015) Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents. Neuron
86:1029–1040. 10.1016/j.neuron.2015.03.063
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2015.03.063</ArticleId>
            <ArticleId IdType="pmc">PMC4443790</ArticleId>
            <ArticleId IdType="pubmed">25937172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rossi J, Balthasar N, Olson D, Scott M, Berglund E, Lee CE, Choi MJ, Lauzon D, Lowell BB, Elmquist JK (2011) Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab
13:195–204. 10.1016/j.cmet.2011.01.010
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2011.01.010</ArticleId>
            <ArticleId IdType="pmc">PMC3033043</ArticleId>
            <ArticleId IdType="pubmed">21284986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Scarr E, Gibbons AS, Neo J, Udawela M, Dean B (2013) Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci
7:55. 10.3389/fncel.2013.00055
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2013.00055</ArticleId>
            <ArticleId IdType="pmc">PMC3642390</ArticleId>
            <ArticleId IdType="pubmed">23653591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Seeman P, Ko F, Tallerico T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry
10:877–883. 10.1038/sj.mp.4001682
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.mp.4001682</ArticleId>
            <ArticleId IdType="pubmed">15852061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Snyder MA, Gao WJ (2013) NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci
7:31. 10.3389/fncel.2013.00031
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2013.00031</ArticleId>
            <ArticleId IdType="pmc">PMC3608949</ArticleId>
            <ArticleId IdType="pubmed">23543703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stefani MR, Moghaddam B (2010) Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur J Pharmacol
639:26–32. 10.1016/j.ejphar.2010.01.028
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2010.01.028</ArticleId>
            <ArticleId IdType="pmc">PMC3359134</ArticleId>
            <ArticleId IdType="pubmed">20371234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun QQ, Zhang Z, Jiao Y, Zhang C, Szabó G, Erdelyi F (2009) Differential metabotropic glutamate receptor expression and modulation in two neocortical inhibitory networks. J Neurophysiol
101:2679–2692. 10.1152/jn.90566.2008
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/jn.90566.2008</ArticleId>
            <ArticleId IdType="pmc">PMC2681425</ArticleId>
            <ArticleId IdType="pubmed">19244358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Urban DJ, Roth BL (2015) DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu Rev Pharmacol Toxicol
55:399–417. 10.1146/annurev-pharmtox-010814-124803
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pharmtox-010814-124803</ArticleId>
            <ArticleId IdType="pubmed">25292433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Volk DW, Eggan SM, Lewis DA (2010) Alterations in metabotropic glutamate receptor 1a and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am J Psychiatry
167:1489–1498. 10.1176/appi.ajp.2010.10030318
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.ajp.2010.10030318</ArticleId>
            <ArticleId IdType="pmc">PMC2997877</ArticleId>
            <ArticleId IdType="pubmed">20889653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang HY, MacDonald ML, Borgmann-Winter KE, Banerjee A, Sleiman P, Tom A, Khan A, Lee KC, Roussos P, Siegel SJ, Hemby SE, Bilker WB, Gur RE, Hahn CG (2018) mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia. Mol Psychiatry. Advance online publication. Retrieved September 13, 2018. doi:10.1038/s41380-018-0234-y. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41380-018-0234-y</ArticleId>
            <ArticleId IdType="pmc">PMC7500805</ArticleId>
            <ArticleId IdType="pubmed">30214040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang H, Westin L, Nong Y, Birnbaum S, Bendor J, Brismar H, Nestler E, Aperia A, Flajolet M, Greengard P (2009) Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling. Science
326:1554–1557. 10.1126/science.1178496
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1178496</ArticleId>
            <ArticleId IdType="pmc">PMC2796550</ArticleId>
            <ArticleId IdType="pubmed">20007903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu M, Hajszan T, Xu C, Leranth C, Alreja M (2004) Group I metabotropic glutamate receptor activation produces a direct excitation of identified septohippocampal cholinergic neurons. J Neurophysiol
92:1216–1225. 10.1152/jn.00180.2004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/jn.00180.2004</ArticleId>
            <ArticleId IdType="pubmed">15044519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu J, Zhu Y, Contractor A, Heinemann SF (2009) mGluR5 has a critical role in inhibitory learning. J Neurosci
29:3676–3684. 10.1523/JNEUROSCI.5716-08.2009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.5716-08.2009</ArticleId>
            <ArticleId IdType="pmc">PMC2746052</ArticleId>
            <ArticleId IdType="pubmed">19321764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu J, Antion MD, Nomura T, Kraniotis S, Zhu Y, Contractor A (2014) Hippocampal metaplasticity is required for the formation of temporal associative memories. J Neurosci
34:16762–16773. 10.1523/JNEUROSCI.2869-13.2014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.2869-13.2014</ArticleId>
            <ArticleId IdType="pmc">PMC4261100</ArticleId>
            <ArticleId IdType="pubmed">25505329</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
